[Therapeutic measures in tardive dyskinesia]

Area of Science:

• Neurology
• Pharmacology

Context:

• Neuroleptic-induced tardive dyskinesia (TD) is a significant side effect of antipsychotic medications.
• Existing treatment options for TD have yielded controversial results, indicating a lack of definitive therapies.

Purpose:

• To review existing literature on TD treatments and suggest improvements for future study designs.
• To evaluate the efficacy and safety of various pharmacological agents in managing TD symptoms.

Summary:

• A review of studies reveals no specific, safe treatment for tardive dyskinesia, highlighting the need for rigorous research.
• Dopamine-related drugs show limited or adverse effects, while cholinergic and GABA-ergic agents require further investigation.
• Anticholinergic drugs are contraindicated, and prevention through careful neuroleptic use is emphasized.

Impact:

• The findings underscore the importance of placebo-controlled, double-blind studies with larger patient cohorts for reliable TD treatment evaluation.
• Recommendations for stable drug dosages, longer study durations, and careful neuroleptic withdrawal are provided to improve research outcomes.
• Emphasis on prevention and cautious neuroleptic prescribing practices is crucial for mitigating TD risk.